10-Q: Celularity Faces Going Concern Doubt Amid Nasdaq Delays

Celularity Inc. reported a net loss for the period ended June 30, 2026, with significant operating losses and substantial doubt about its ability to continue as a going concern, alongside ongoing Nasdaq compliance challenges.

Summary

• Celularity Inc. reported a net loss for the quarter ended June 30, 2026, with total revenues of $5.4 million, down from $5.7 million in the prior year period.
• The company experienced a loss from operations of $4.2 million for the quarter, compared to a loss of $15.9 million in the prior year.
• Significant operating losses and a working capital deficit of $53.3 million as of June 30, 2026, raise substantial doubt about the company's ability to continue as a going concern.
• Celularity received notices from Nasdaq regarding non-compliance with market value and minimum bid price requirements, though it has since regained compliance.
• The company is actively seeking additional financing and strategic partnerships to address its liquidity needs and operational challenges.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to substantial going concern doubts, Nasdaq non-compliance issues, and significant operating losses, despite some recent revenue improvements.

Positives

• Product sales increased by 70.7% to $4.1 million for the three months ended June 30, 2026, compared to $2.4 million in the prior year period.
• Total revenues for the six months ended June 30, 2026, were $9.3 million, a decrease from $17.2 million in the prior year, but the company reported a net income of $1.6 million for the six-month period, a significant improvement from a net loss of $44.3 million in the prior year.
• The company recognized a gain of $6.7 million on the SLS Settlement.
• Operating expenses decreased significantly by 55.2% for the three months ended June 30, 2026, compared to the prior year period, largely due to reductions in SG&A and R&D expenses.
• The company regained compliance with Nasdaq's minimum bid price and market value of listed securities requirements.

Negatives

• The company has substantial doubt about its ability to continue as a going concern within one year from the issuance date of the financial statements.
• Total revenues decreased by 5.3% to $5.4 million for the three months ended June 30, 2026, compared to $5.7 million in the prior year.
• Revenues from Services decreased by 48.9% and License, royalty and other revenues decreased by 65.5% for the three months ended June 30, 2026.
• The company incurred a loss on settlement with Helena of $2.5 million for the three and six months ended June 30, 2026.
• Significant material weaknesses in internal control over financial reporting were identified, including issues with control environment, risk assessment, control activities, information and communication, monitoring, and privileged access.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring operating losses, working capital deficits, insufficient cash reserves, debt maturities, and Nasdaq non-compliance status.
• Failure to secure sufficient additional capital or generate positive cash flows from operations could force the company to pursue strategic alternatives, including curtailing operations, monetizing assets, selling the business, or seeking bankruptcy protection.
• Delisting from Nasdaq could severely impair the liquidity and market value of the company's common stock and restrict its ability to raise additional capital.
• The company is subject to ongoing litigation and potential liabilities, including a Civil Investigative Demand from the U.S. Attorneys Office.
• The company's ability to regain and maintain compliance with Nasdaq listing rules is not assured.

Future Outlook

The company is actively pursuing additional financing through equity offerings, debt financings, strategic collaborations, or other transactions to fund operations and meet obligations. Revenue growth is expected to be required to achieve break-even operating cash flows. The company is also exploring commercialization of investigational cellular therapies in jurisdictions with alternative treatment pathways.

Management Comments

• Management has evaluated the Company's current financial position, liquidity, capital resources, and projected cash flows and has determined that there is substantial doubt about the Company's ability to continue as a going concern.
• The Company needs to secure additional financing; however, there is no assurance that financing can be raised or at acceptable terms.
• In early 2026, the Company implemented operational restructuring initiatives aimed at reducing overhead costs, streamlining headcount, and reallocating resources toward core commercial opportunities.
• Management believes that increased sales are required to achieve break even operating cash flows in the next 12 months, however there is no assurance this will be achieved and significant operating losses and net cash uses for operations may continue for the foreseeable future.
• We intend to regain compliance with Nasdaq listing requirements; however, there can be no assurance that we will be able to do so within any applicable period or that its securities will continue to be listed on Nasdaq.

Industry Context

StockSavvy.ai notes that Celularity operates in the highly competitive and capital-intensive regenerative medicine and cellular therapy sector. The company's focus on longevity and age-related diseases aligns with growing market interest, but the path to commercialization and profitability is fraught with significant scientific, regulatory, and financial hurdles, as evidenced by its ongoing struggles.

Comparison to Industry Standards

• Companies in the regenerative medicine sector often require substantial upfront investment in R&D and clinical trials, with long development timelines before potential market approval.
• Many early-stage biotech companies face similar going concern issues and rely heavily on continuous financing rounds, making Nasdaq compliance and liquidity critical.
• Competitors in cell therapy are also navigating complex regulatory pathways with the FDA, and success often hinges on demonstrating clear clinical efficacy and safety profiles.
• The trend towards strategic partnerships and licensing deals, as seen with the NexGel transaction, is common in the industry to de-risk development and generate revenue streams.

Management Changes

Legal Proceedings

• Civil Investigative Demand from the U.S. Attorneys Office for the Eastern District of Pennsylvania relating to claims submitted to Medicare, Medicaid, or other federal insurers for services involving injectable human tissue therapy products.
• Celularity Inc. v. Evolution Biologyx, LLC, et al.: Settlement reached on major issues, with documentation being finalized.
• TCWGlobal v. Celularity Inc.: Case settled in April 2026 after default on settlement payments.
• Hackensack Meridian Health v. Celularity Inc.: Amount due reduced to $668,000 after joint review; company defaulted on payments.
• Shareholder Derivative Action (Dorrance v. Diamandis): Settled for $3 in cash and $300 in restricted stock to plaintiffs counsel.
• Helena Settlement: Company entered into a settlement agreement to resolve default notices and restructure obligations, but missed subsequent installment payments.
• BioCellgraft, Inc. Default Notice: Company delivered a notice of default for unpaid license fee installments.

Related Party Transactions

• CEO's daughter is employed by the Company as Vice President, Corporate Strategy & Business Development.
• The Company borrowed $0.3 million from its Chief Operating Officer, Steven N. Gordon, on June 19, 2026, with interest at 4% per annum.
• The Company's CEO, Robert J. Hariri, M.D., Ph.D., and Director, Peter Diamandis, M.D., are founding partners of Fountain Life Management LLC, with whom the Company has a Technology Services Agreement.
• The Company has outstanding debt obligations related to loans from its CEO, Steven N. Gordon.

Stakeholder Impact

• Shareholders: Potential delisting from Nasdaq, significant dilution from future capital raises, and continued uncertainty regarding the company's going concern status negatively impact shareholder value and liquidity.
• Creditors: The company's financial distress and going concern issues increase the risk of default on debt obligations.
• Employees: The company's financial instability and restructuring efforts may lead to job insecurity and potential workforce reductions.
• Customers: The company's focus shift from biomaterials to cell therapy, coupled with financial challenges, could impact the availability and development of its existing product lines.
• Suppliers: Potential delays or defaults in payments could strain relationships with suppliers.

Next Steps

• The company must regain compliance with Nasdaq listing rules regarding market value and minimum bid price.
• The company must file its delinquent Form 10-Q for the period ended June 30, 2026, by November 16, 2026.
• Management is actively pursuing additional financing and strategic partnerships.
• The company will continue to develop its cellular therapy candidates, including cenplacel-L and NK cells.
• The company will continue to provide manufacturing and biobanking services to third parties.

Key Dates

Recommendation

The filing indicates severe financial distress, including substantial going concern doubts, ongoing Nasdaq non-compliance issues (despite recent regain of compliance), significant operating losses, and a history of missed payments and defaults. While there are some positive revenue trends in product sales and a net income for the six-month period (largely due to tax benefits), these are overshadowed by the fundamental risks to the company's continued operation. The need for significant additional capital, coupled with the potential for delisting and the complex legal and settlement issues, presents a high-risk investment profile.

Keywords

regenerative medicine, cellular therapy, placenta-derived, biobanking, longevity, biomaterials, clinical trials, Nasdaq compliance